Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 13;4(3):273-82.
doi: 10.1002/mgg3.202. eCollection 2016 May.

Sideroblastic anemia: functional study of two novel missense mutations in ALAS2

Manuel Méndez  1 , María-Isabel Moreno-Carralero  1 , Marta Morado-Arias  2 , María-Cristina Fernández-Jiménez  3 , Silvia de la Iglesia Iñigo  4 , María-José Morán-Jiménez  1
Affiliations

Sideroblastic anemia: functional study of two novel missense mutations in ALAS2

Manuel Méndez et al. Mol Genet Genomic Med. .

Abstract

Background: X-linked sideroblastic anemia (XLSA) is a disorder characterized by decreased heme synthesis and mitochondrial iron overload with ringed sideroblasts in bone marrow. XLSA is caused by mutations in the erythroid-specific gene coding 5-aminolevulinate synthase (ALAS2). Anemia in XLSA is extremely variable, characteristically microcytic and hypochromic with poikilocytosis, and the red blood cell distribution width is increased and prominent dimorphism of the red cell population. Anemia in XLSA patients responds variably to supplementation with pyridoxine.

Methods and results: We report four patients with XLSA and three mutations in ALAS2: c.611G>A (p.Arg204Gln), c.1218G>T (p.Leu406Phe) and c.1499A>G (p.Tyr500Cys). The in silico predictions of three ALAS2 mutations and the functional consequences of two ALAS2 mutations were assessed. We performed in silico analysis of these mutations using ten different softwares, and all of them predicted that the p.Tyr500Cys mutation was deleterious. The in vitro prokaryotic expression showed that the p.Leu406Phe and p.Tyr500Cys mutations reduced the ALAS2 specific activity (SA) to 14% and 7% of the control value, respectively.

Conclusion: In view of the results obtained in this study, a clear relationship between genotype and phenotype cannot be established; clinical variability or severity of anemia may be influenced by allelic variants in other genes or transcription factors and environmental conditions.

Keywords: ALAS2; in silico analysis; prokaryotic expression; sideroblastic anemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Peripheral blood smear of patient 4 showing anisopoikilocytosis (arrows), microcytosis (square), and hypochromia (circle) with basophilic stippling (asterisk). (B and C) Bone marrow smears of patient 4 showing erythroid hyperplasia (asterisk) without dysplasia and ringed sideroblasts (arrow).
Figure 2
Figure 2
Electropherograms show the mutations identified in this study: control sequences (left panels) and mutated sequences (right panels) of 5‐aminolevulinate synthase ALAS2 gene (NG_008983.1).
See this image and copyright information in PMC

References

    1. Aivado, M. , Gattermann N., Rong A., Giagounidis A. A., Prall W. C., Czibere A., et al. 2006. X‐linked sideroblastic anemia associated with a novel ALAS2 mutation and unfortunate skewed X‐chromosome inactivation patterns. Blood Cells Mol. Dis. 37:40–45. - PubMed
    1. Astner, I. , Schulze J. O., van den Heuvel J., Jahn D., Schubert W. D., and Heinz D. W.. 2005. Crystal structure of 5‐aminolevulinate synthase, the first enzyme of heme biosynthesis, and its link to XLSA in humans. EMBO J. 24:3166–3177. - PMC - PubMed
    1. Barton, J. C. , Lee P. L., Bertoli L. F., and Beutler E.. 2005. Iron overload in an African American woman with SS hemoglobinopathy and a promoter mutation in the X‐linked erythroid‐specific 5‐aminolevulinate synthase (ALAS2) gene. Blood Cells Mol. Dis. 34:226–228. - PubMed
    1. Bekri, S. , May A., Cotter P. D., Al‐Sabah A. I., Guo X., Masters G. S., et al. 2003. A promoter mutation in the erythroid‐specific 5‐aminolevulinate synthase (ALAS2) gene causes X‐linked sideroblastic anemia. Blood 102:698–704. - PubMed
    1. Bishop, D. F. , Tchaikovskii V., Hoffbrand A. V., Fraser M. E., and Margolis S.. 2012. X‐linked sideroblastic anemia due to carboxyl‐terminal ALAS2 mutations that cause loss of binding to the beta‐subunit of succinyl‐CoA synthetase (SUCLA2). J. Biol. Chem. 287:28943–28955. - PMC - PubMed

LinkOut - more resources